Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
TEMPLE CITY, Calif., July 31, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2017 financial results after the market closes on Monday, August 7, 2017. The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science Officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investor section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 55000778. An audio replay will be available in the investors section of the company’s website or by calling (855) 859-2056 using passcode 55000778 through August 14, 2017.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, [email protected] Chris Danne, 415-217-5865, [email protected]
